Vulcan Two Group, the AIM-listed company building Britain’s leading regulated ePharmacy platform, has raised £40 million through a share placing to fund the acquisition of three UK online pharmacy businesses.
The Leeds investment story sees the company acquire CloudRx Holdings, Hyperdrug Pharmaceuticals and Webmed Pharmacy for a total consideration of approximately £41.7 million, with £37.1 million payable in cash and the remainder in shares.
The acquisitions, which require shareholder approval at a general meeting on 17 March, collectively constitute a reverse takeover under AIM rules. The enlarged group is projected to generate over £35 million in annual revenue, with a significant recurring portion from prescription services.
Michael Kraftman, Chief Executive Officer of Vulcan Two, commented:
“We are delighted to announce the Acquisitions which will serve as the foundation on which we will aim to build the UK’s leading regulated ePharmacy platform. This significant milestone marks the beginning of an exciting new chapter as we work to integrate the Targets and pursue our strategy as stated at IPO, supported by strong market tailwinds. We believe we are well positioned for the future, and look forward with great excitement to further opportunities ahead.”
Leeds Investment Community Backs Digital Health Growth
The three target businesses operate in the growing UK ePharmacy market, dispensing NHS and private prescriptions online alongside health and wellness products. The consolidation play aims to create economies of scale in marketing, technology and purchasing while expanding the customer base across business-to-consumer and business-to-business channels.
Vulcan Two plans to implement an Enterprise Resource Planning system across the enlarged group to integrate operations and drive efficiency. The Leeds investment raise included significant participation from related parties including Octopus Investments, Gresham House Asset Management and Dowgate Group, all deemed fair and reasonable by independent directors.
The acquisitions accelerate Vulcan Two’s buy-and-build strategy in regulated ePharmacy services, a sector experiencing growth as consumers increasingly access prescriptions and health products online. The enlarged group will compete with established players in digital pharmacy services while maintaining full regulatory compliance.
Net proceeds from the placing will satisfy initial cash consideration, provide working capital for the enlarged group, and support future bolt-on acquisitions as Vulcan Two continues building its national platform.
Full release: https://www.londonstockexchange.com/news-article/VUL/proposed-placing-and-acquisitions/17479206
Why this matters for Leeds
Vulcan Two’s £40 million fundraise shows Leeds-based companies can access serious institutional capital for ambitious growth plans in regulated sectors like digital healthcare. The company’s successful buy-and-build strategy demonstrates Leeds entrepreneurs can execute national consolidation plays, not just build individual startups. This strengthens Leeds’ reputation as a home for innovative healthcare technology businesses and validates investor confidence in the city’s ability to produce scaled digital health platforms that compete nationally.
